Myomo (MYO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Myomo (MYO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Myomo (MYO) delivered earnings and revenue surprises of +12.50% and +9.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad (BIO) delivered earnings and revenue surprises of +1.53% and -0.83%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Myomo (MYO) delivered earnings and revenue surprises of +30.00% and +14.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Myomo (MYO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Myomo (MYO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Myomo (MYO) delivered earnings and revenue surprises of +21.74% and +8.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Myomo (MYO) delivered earnings and revenue surprises of +5.88% and +11.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of +14.16% and +0.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Myomo (MYO) delivered earnings and revenue surprises of +18.18% and +8.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?